Aims: To evaluate the effect of addition of T3 to L-T4 treatment in children with congenital hypothyroidism (CH) who have inappropriately elevated thyroid-stimulating hormone (TSH) levels despite high normal serum T4 levels on L-T4 treatment. Methods: Ten children (age 7.1 ± 2 years) with CH whose TSH levels were persistently high despite euthyroidism and can only be normalized with hyperthyroidism were included. L-T4 treatment was switched to T3+L-T4 combination (Bitiron® tablet 50 µg L-T4 + 12.5 µg triiodothyronine). The patients received 50% of their usual L-T4 dose as L-T4 and the remaining half as T3 in a 4:1 ratio. The dose of T3+L-T4 was titrated to achieve normal TSH levels. Thyroid hormones and biochemical markers were followed for 1 year. Results: Euthyrotropinemia was achieved at the 7th month (mean) of combination (T3+L-T4) treatment. Serum T4 and fT4 were lower and T3 was higher during combination compared to L-T4 treatment. LDL-cholesterol decreased and ALP increased in the euthyrotropinemic state. Vital signs were similar at hyperthyrotropinemia and euthyrotropinemia. Conclusion: T3+L-T4 treatment provides euthyrotropinemia without causing hyperthyroidism in children with CH and inappropriate hyperthyrotropinemia. Our data strongly suggest that decreased negative feedback due to lower T3 levels at the pituitary level is the main reason for persistent hyperthyrotropinemia.

Keywords:
Congenital hypothyroidism, L-T4, T4+T3 treatment, Combination treatment, Inappropriate hyperthyrotropinemia
1.
McCrossin RB, Sheffield LJ, Robertson EF: Persisting abnormality in the pituitary-thyroid axis in congenital hypothyroidism; in Stockigt JR, Nagataki S (eds): Thyroid Research VII. Canberra, Journal of the Australian Academy of Science, 1980, pp 37–40.
2.
Sack J, Shafrir Y, Urbach D, Amado AO: Thyroid stimulating hormone, prolactin, and growth hormone responses to thyrotropin releasing hormone in treated children with congenital hypothyroidism. Pediatr Res 1985;19:1037–1039.
3.
Grant DB, Fuggle PW, Smith I: Increased plasma thyroid stimulating hormone in treated congenital hypothyroidism: relation to severity of hypothyroidism, plasma thyroid hormone status, and daily dose of thyroxine. Arch Dis Child 1993;69:555–558.
4.
Heyerdahl S, Kase BF: Significance of elevated serum thyrotropin during treatment of congenital hypothyroidism. Acta Paediatr 1995;84:634–638.
5.
Roger PP, Dumont JE: Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: effects of thyrotropin, cyclic AMP and growth factors. Mol Cell Endocrinol 1984;36:79–93.
6.
Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum TSH level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008;93:809–814.
7.
Escobar-Morreale HF, Escobar del Rey F, Obregon MJ, Morreale de Escobar G: Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues the thyroidectomized rat. Endocrinology 1996;137:2490–2502.
8.
Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Monreale de Escobar G: Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995;96:2828–2838.
9.
Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R: Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartmental analysis. Am J Physiol 1990;258:E715–E726.
10.
Raza J, Hindmarsh PC, Brook CG: Thyrotoxicosis in children: thirty years experience. Acta Paediatr 1999;88:937–941.
11.
Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sanger E, Engel G, Hamm AO, Nauck M, Meng W: Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004;60:750–757.
12.
Toft AD: Thyroid hormone replacement: one hormone or two? N Engl J Med 1999;340:469–470.
13.
Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005;142:412–424.
14.
Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, vanWeert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratio’s compared with levothyroxine monotherapy in primary hypothyroidism; a double blind, randomized controlled clinical trial. J Clin Endocrinol Metab 2005;90:2666–2674.
15.
Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005;90:4946–4954.
16.
Cassio A, Cacciari E, Cicognani A, Damiani G, Missiroli G, Corbelli E, Balsamo A, Bal M, Gualandi S: Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003;111:1055–1060.
17.
Silva JE: Pituitary-thyroid relationships in hypothyroidism. Baillières Clin Endocrinol Metab 1988;2:541–565.
18.
Silva JE, Leonard JL: Regulation of rat cerebrocortical and adenohypophyseal type II 5′-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. Endocrinology 1985;116:1627–1635.
19.
Terasaki T, Pardridge WM: Differential binding of thyroxine and triiodothyronine to acidic isoforms of thyroid hormone binding globulin in human serum. Biochemistry 1988;27:3624–3628.
20.
Silva JE, Larsen PR: Pituitary nuclear 3,5,3′- triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. Science 1977;198:617–620.
21.
Larsen PR, Silva JE, Kaplan MM: Relationships between circulating and intracellular hormones. Endocrinol Rev 1981;2:87–102.
22.
Silva JE, Leonard JL, Crantz FR, Larsen PR: Evidence of two tissue specific pathways for in vivo thyroxine 5′-deiodination in the rat. J Clin Invest 1982;69:1176–1184.
23.
Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM: A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008;93:3075–3081.
24.
Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D’Arcangelo P, Dallapiccola B, Filetti S, Trischitta V: Type 2 deiodinase polymorphism (threonine 92 alanine) predictsL-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008;93:910–913.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.